Trends and outcomes of direct oral anticoagulant use in patients with cancer: a nationwide cohort study

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Mr Anders Holt

Herlev and Gentofte Hospital, Copenhagen (Denmark)

4 More presentations in this session

Presentation thumbnail

LOw-dose RAbeprazole therapy for reducing gastrointestinal events in patients with High Bleeding Risk (LORA-HBR): a prospective, multicenter, interventional study

Assistant Professor E. Park (Seoul, KR)

Abstract Slides Video

Presentation thumbnail

Long-term outcomes of direct oral anticoagulants versus warfarin for chronic thromboembolic pulmonary hypertension: a reconstructed individual patient data meta-analysis

Doctor A. Chng (Singapore, SG)

Abstract Slides Video

Presentation thumbnail

Effectiveness and safety of direct oral anticoagulants versus vitamin k antagonists in patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis

Mr K. Chagas (Itaperuna, BR)

Abstract Slides Video

Presentation thumbnail

The efficacy and safety of direct oral anticoagulants compared to warfarin for LV thrombus resolution

Doctor S. Azevedo (Lisbon, PT)

Abstract Slides Video

Access the full session

Session thumbnail

Anticoagulation pharmacotherapy updates

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Session

Personalising antithrombotic therapy in patients with cancer: what every cardiologist should know

Congress Session

Rethinking cancer-associated venous thromboembolism (VTE): integrating evidence into practice

Congress Presentation

Effective venous thromboembolism treatment in high bleeding- risk patients

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources